4/A: Heron Therapeutics Director Susan Rodriguez Reports Stock and Option Grants

Director Susan Rodriguez reports acquisition of Heron Therapeutics stock and options via grant.

Summary

• Susan Rodriguez, a director of Heron Therapeutics, reported changes in beneficial ownership.
• On January 31, 2025, Rodriguez acquired 17,950 shares of common stock through restricted stock units and 35,900 stock options.
• The restricted stock units vest in full on January 31, 2026, each representing a right to receive one share of common stock.
• The stock options, with an exercise price of $1.7, vest in 12 equal monthly installments starting one month after the grant date and expire on January 31, 2035.
• Following the reported transactions, Rodriguez directly owns 87,180 shares of common stock and 35,900 stock options.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Positives

• The grant of stock and options to a director could be seen as an incentive to align their interests with those of the shareholders.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common compensation practices for directors in publicly traded companies like Heron Therapeutics.
• The vesting schedules and exercise prices are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The grant of stock and options to a director can impact shareholder value depending on the company's performance.

Key Dates